Safety and efficacy of cidofovir for adenovirus infectio
Not Applicable
- Conditions
- adenovirus infection
- Registration Number
- JPRN-UMIN000004336
- Lead Sponsor
- Hematology, Osaka City University, Graduate School of Meicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 21
Inclusion Criteria
Not provided
Exclusion Criteria
Subjects who meet any of the following criteria are not eligible. 1) Positive for anti-HIV antibody 2) Positive for hepatitis B surface antigen or HBV-DNA 3) Positive for anti-HCV antibody 4) Creatinine clearance lower than 0.1ml/min/kg calculated by the Cockcroft-Gault formula 5) Patients who have coexisting sinusoidal obstruction syndrome 6) Known hypersensitivity to cidofovir 7) Known hypersensitivity to probenecid 8) Patients who are ineligible for this study as judged by the investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Disappearance of signs and symptoms in association with adenovirus infection Elimination of adenovirus from the tissue specimen on which diagnosis of adenovirus infection was made.
- Secondary Outcome Measures
Name Time Method Reduction of viral load Improvement of clinical symptoms, imaging findings and abnormal laboratory values in association with adenovirus infection.